Browse the world's most comprehensive database of hedge fund investor letters, sorted by recent quarter. Access primary source research from leading institutional managers.
| Quarter | Letter Date | Fund Name | QTD | YTD | Tickers | Themes | Quick Take |
|---|---|---|---|---|---|---|---|
Buyside Digest is not affiliated with, and does not endorse, ClearBridge Investments All Cap Growth. This analysis is provided for institutional research purposes only and is not investment advice.
"ClearBridge All Cap Growth underperformed in Q2 2025's risk-on rebound due to diversified positioning versus concentrated benchmark. Health care holdings weighed on performance while AI and streaming names contributed."
ClearBridge All Cap Growth Strategy underperformed its Russell 3000 Growth Index benchmark in Q2 2025 despite a strong market rebound from tariff uncertainty. Growth stocks led the recovery with technology and communication services sectors outperforming as risk-on sentiment returned. The strategy's diversified exposure compared to the concentrated benchmark created headwinds after serving as a tailwind in the turbulent first quarter. Key contributors included Netflix, which delivered robust execution with double-digit revenue growth, and Broadcom, which maintained strong execution in AI custom silicon development. The health care sector was the primary detractor, with UnitedHealth Group missing earnings and Vertex Pharmaceuticals facing European weakness. The team took advantage of volatility to initiate four new positions, replacing Eli Lilly with Novo Nordisk in GLP-1 treatments and adding Alnylam Pharmaceuticals in RNA interference technology. They also added Synopsys in electronic design automation and Palantir Technologies in AI-powered data analytics. The portfolio is positioned with holdings that have strong market positions and pricing power to weather potential tariff-related cost inflation while maintaining balanced exposure to both offensive and defensive growth characteristics.
Sign in or create a free account to unlock full commentary, extracted equity pitches, and direct outbound manager source links with your 3 quarterly credits.
Algorithmic conviction, macroeconomic posture, and risk appetite signals extracted from this quarterly letter with qualitative explanations.
Market Conviction
The managers demonstrate moderate-high conviction through specific position changes with detailed rationales for each addition and exit. They name individual holdings, explain thesis drivers, and size considerations (mindful of Palantir's valuation). The letter discusses 20 specific companies with clear investment reasoning, though the diversified nature and hedged language around macro conditions prevents higher scoring.
Growth Outlook
The managers acknowledge market recovery and risk-on sentiment but express caution about bumpy macroeconomic backdrop ahead. They note solid gains but emphasize positioning for various economic scenarios rather than expressing strong bullish conviction.
Risk Appetite
The team actively deployed capital by initiating four new positions while exiting four others, showing selective risk appetite. They took advantage of volatility to upgrade exposure in biopharmaceuticals and high-growth IT, indicating moderate risk-on positioning.
Capital Deployment
The team initiated four new positions while exiting four others, representing capital rotation rather than net deployment. No cash level changes mentioned, and the activity appears to be rebalancing existing exposure rather than putting new cash to work.
Forward Guidance
Forward guidance is cautious with emphasis on positioning for bumpy macroeconomic conditions. While they express confidence in holdings' ability to weather challenges, the tone suggests measured deployment rather than aggressive risk-taking.
Language Signal
Language balances opportunity recognition (attractive valuations, solid execution, strong market positions) with risk awareness (bumpy backdrop, tariff pressures, execution challenges). Slightly more constructive than cautious but well-balanced overall.
Perceived Risk
Managers identify several specific risks including tariff impacts on costs and pharmaceutical imports, Medicare Advantage reimbursement pressures, and academic/government spending cuts. They expect a bumpy macroeconomic backdrop and discuss sector-specific headwinds, showing moderate risk awareness without alarm.
Opportunity Density
The team found four attractive new investment opportunities during the quarter and expressed excitement about new ideas put to work. They see selective opportunities in upgraded biopharmaceutical and high-growth IT exposure, suggesting a reasonably rich opportunity set in specific areas.
Time Horizon
The managers emphasize long-term strategy and positioning for various economic scenarios rather than near-term catalysts. They discuss multi-year growth drivers for companies like Broadcom's AI business and Netflix's global streaming market, indicating a medium to long-term investment horizon of 2-5 years.
